Abstract
Transforming growth factor beta isoforms (TGF-β1, -β2, and -β3) are cytokines associated with a wide range of biological processes in oncology including tumor cell invasion and migration, angiogenesis, immunosuppression, as well as regulation of tumor stem cell properties. Hence, blocking the TGF-β signaling pathways may have a multifold therapeutic benefit for the treatment of solid tumors. Here, we describe the identification and selection processes for the development of highly potent and selective chemically modified antisense oligodeoxynucleotides (fully phosphorothioate locked nucleic acid gapmers) allowing effective and selective suppression of TGF-β isoform expression in cell-based assays and in vivo preclinical models.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Moustakas A, Miyazawa K (2013) TGF-β in human diseases. Springer
Sheen YY, Kim MJ, Park SA et al (2013) Targeting the transforming growth factor-β signaling in cancer therapy. Biomol Ther 21:323–331
Hinck AP, Archer SJ, Qian SW et al (1996) Transforming growth factor beta 1: three-dimensional structure in solution and comparison with the X-ray structure of transforming growth factor beta 2. Biochemistry 35:8517–8534
Hinck AP, O’Connor-McCourt MD (2011) Structures of TGF-β receptor complexes: implications for function and therapeutic intervention using ligand traps. Curr Pharm Biotechnol 12:2081–2098
Hinck AP (2012) Structural studies of the TGF-βs and their receptors—insights into evolution of the TGF-β superfamily. FEBS Lett 586:1860–1870
Zamecnik PC, Stephenson ML (1978) Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligonucleotide. Proc Natl Acad Sci U S A 75:280–284
Koch T (2013) LNA antisense: a review. Curr Phys Chem 3:55–68
Obika S, Morio JA, Nanbu D et al (1997) Synthesis and conformation of 3′-O,4′-C-methyleneribonucleosides, novel bicyclic nucleoside analogues for 2′,5′-linked oligonucleotide modification. Chem Commun 1643–1644
Wengel J (1999) Synthesis of 3′-C- and 4′-C-branched oligodeoxynucleotides and the development of locked nucleic acid (LNA). Acc Chem Res 32:301–310
Sohail M, Southern EM (2000) Selecting optimal antisense reagents. Adv Drug Deliv Rev 44:23–34
Smith L, Andersen KB, Hovgaard L et al (2000) Rational selection of antisense oligonucleotide sequences. Eur J Pharm Sci 11:191–198
Lieber M, Mazzetta J, Nelson-Rees W, Kaplan M et al (1975) Establishment of a continuous tumor-cell line (panc-1) from a human carcinoma of the exocrine pancreas. Int J Cancer 15:741–747
Thiede MA, Strewler GJ, Nissenson RA, Rosenblatt M et al (1988) Human renal carcinoma expresses two messages encoding a parathyroid hormone-like peptide: evidence for the alternative splicing of a single- copy gene. Proc Natl Acad Sci U S A 85:4605–4609
Bates PJ, Kahlon JB, Thomas SD et al (1999) Antiproliferative activity of G-rich oligonucleotides correlates with protein binding. J Biol Chem 274:26369–26377
Vollmer J, Jepsen JS, Uhlmann E, Schetter C et al (2004) Modulation of CpG oligodeoxynucleotide-mediated immune stimulation by locked nucleic acid (LNA). Oligonucleotides 14:23–31
Grünweller A, Wyszko E, Bieber B, Jahnel R et al (2003) Comparison of different antisense strategies in mammalian cells using locked nucleic acids, 2′-O-methyl RNA, phosphorothioates and small interfering RNA. Nucleic Acids Res 31:3185–3193
Vester B, Wengel J (2004) LNA (locked nucleic acid): high-affinity targeting of complementary RNA and DNA. Biochemistry 43:13233–13241
https://www.exiqon.com/ls/Pages/ExiqonOligoOptimizerTool.aspx
Souleimanian N, Deleavey GF, Soifer H, Wang S et al (2012) Antisense 2′-deoxy, 2′-fluoroarabino nucleic acid (2′F-ANA) oligonucleotides: in vitro gymnotic silencers of gene expression whose potency is enhanced by fatty acids. Mol Ther Nucleic Acids 1:e43
Stein CA, Hansen JB, Lai J, Wu S et al (2010) Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents. Nucleic Acids Res 38:e3
Swayze EE, Siwkowski AM, Wancewicz EV, Migawa MT et al (2007) Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals. Nucleic Acids Res 35:687–700
Hagedorn PH, Yakimov V, Ottosen S, Kammler S et al (2013) Hepatotoxic potential of therapeutic oligonucleotides can be predicted from their sequence and modification pattern. Nucleic Acid Ther 23:302–310
Soifer HS, Koch T, Lai J, Hansen B et al (2012) Silencing of gene expression by gymnotic delivery of antisense oligonucleotides. Methods Mol Biol 815:333–346
Acknowledgement
The authors wish to acknowledge and recognize superb technical and scientific support from Marcus Kielmanowicz, Axolabs GmbH (Kulmbach, Germany), and Oncodesign (Dijon, France).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer Science+Business Media New York
About this protocol
Cite this protocol
Jaschinski, F., Korhonen, H., Janicot, M. (2015). Design and Selection of Antisense Oligonucleotides Targeting Transforming Growth Factor Beta (TGF-β) Isoform mRNAs for the Treatment of Solid Tumors. In: Walther, W., Stein, U. (eds) Gene Therapy of Solid Cancers. Methods in Molecular Biology, vol 1317. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-2727-2_9
Download citation
DOI: https://doi.org/10.1007/978-1-4939-2727-2_9
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-2726-5
Online ISBN: 978-1-4939-2727-2
eBook Packages: Springer Protocols